Research Article Details
| Article ID: | A36841 |
| PMID: | 17128639 |
| Source: | Postgrad Med |
| Title: | Noninvasive tests for liver fibrosis. |
| Abstract: | There is little doubt that we need fibrosis markers or scoring systems that have proven utility in assessing common hepatic diseases, such as hepatitis C and NASH. Despite multiple research studies, none has yet proved to be of clinical value. The most likely benefit of these tests will be to distinguish between minimal and advanced fibrosis or cirrhosis. Several panels of markers have shown utility in this regard but are not yet established as useful for all hepatic diseases. Until they have been validated and clinically accepted, liver biopsy will continue to be the "gold standard" for assessing liver fibrosis. |
| DOI: | 10.1080/00325481.2006.11446044 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|